Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure
Status:
Terminated
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
Pharmacologic approaches to increase levels or actions of the vasodilatory peptide
angiotensin-(1-7) are currently in development for the treatment of hypertension based on
findings from animal models. There are limited and contradictory clinical studies, however,
and it is not clear if this peptide regulates blood pressure in humans. The purpose of this
study is to better understand the cardiovascular effects angiotensin-(1-7) in human
hypertension, and to examine interactions of this peptide with the autonomic nervous system.
The investigators propose that the difficulties in showing angiotensin-(1-7) cardiovascular
effects in previous clinical studies relates to the buffering capacity of the baroreceptor
reflex to prevent changes in blood pressure. Autonomic failure provides the ideal patient
population to test this hypothesis. These patients have loss of baroreflex buffering and have
low levels of angiotensin-(1-7) in blood. The investigators will test if angiotensin-(1-7)
infusion can lower blood pressure in patients with autonomic failure, and will determine the
hemodynamic and hormonal mechanisms involved in this effect.
Phase:
Early Phase 1
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center
Treatments:
Angiotensin I (1-7) Angiotensin II Angiotensinogen